

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN (print): 1109-6535; ISSN (online): 1790-6245

Volume 9, 2012

INDEX

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
R. Abagyan The Scripps Research Institute, La Jolla, CA, USA
F. Ahmed Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
S. Antonarakis Division of Medical Genetics, University of Geneva Medical School, Switzerland
D.-T. Bau Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan
M.R. Chance Case Western Reserve University, Center for Proteomics and Bioinformatics, Cleveland, OH, USA
A.M. Chinnaiyan Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
B.F.C. Clark Department of Molecular Biology, University of Aarhus, Denmark
R. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
N. E. Davidson University of Pittsburgh, Cancer Institute, Pittsburgh, PA, USA
I. Dunham European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, UK
T. Efferth Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
J.A. Fernandes-Pol Metalloproteomics, LLC, Chesterfield, MO, USA
C.V. Forst Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA
M. Fountoulakis F. Hoffman-La Roche Pharmaceutical Research, Basel, Switzerland
D.S. Gerhard NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
T.R. Golub Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
J. Gordon Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
- J.W. Gray** OHSU Knight Cancer Institute, Biomedical Engineering, Portland, OR, USA
B.B. Haab Van Andel Research Institute, Grand Rapids, MI, USA
C.-H. Heldin Ludwig Institute for Cancer Research, Uppsala, Sweden
J.D. Hoheisel Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
R.P. Huang RayBiotech, Inc., Norcross, GA, USA
T.H.M. Huang Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
- S.C. Jhanwar** Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
V.C. Jordan Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA
J. Ju Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
A. Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
O.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
K. Khalili College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- D.G. Kieback** Department of Obstetrics and Gynecology, Elblandklinikum, Riesa (Dresden), Germany
S.D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece
B. Léylund-Jones Edith Sanford Breast Cancer Research, Sanford Health, Sioux Falls, SD, USA
P. Lichter Deutsches Krebsforschungszentrum, Heidelberg, Germany
A. Lindblom Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
G. Lubec Department of Pediatrics, University of Vienna, Austria
J. Lyons-Weiler Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
P.J. McCormick The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
F. Mitelman Department of Clinical Genetics, University Hospital, Lund, Sweden
P. Nelson Fred Hutchinson Cancer Research Center, Seattle, WA, USA
C. Nicot Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA

- L. O'Driscoll** School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
I. Pastan Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA
C.D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
J.S. Rader Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
A. Raouf Department of Immunology, University of Manitoba, Manitoba Institute of Cell Biology (MICB), Winnipeg, MB, Canada
G. Rasty Department of Anatomic Pathology, University Health Network, University of Toronto, Toronto, ON, Canada
G. Rechavi Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel
R.H. Reeves Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
Y. Sakaki Toyohashi University of Technology, Toyohashi, Japan
C. Sansom The School of Crystallography, Birbeck College, University of London, UK
N.A. Saunders Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
B.W. Schäfer Department of Oncology, University Children's Hospital, Zurich, Switzerland
J. Schneider Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
O.J. Semmes Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
G.V. Sherbet University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
K.K. Singh University of Alabama at Birmingham, Department of Genetics/Cancer Research, Birmingham, AL, USA
S. Smith City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
J.C. Strefford Cancer Science Division, Southampton General Hospital, Southampton, UK
J.M. Trent Tgen, Phoenix, AZ, USA
G. Tsangaris Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
L.-C. Tsui University of Hong Kong, Hong Kong
G.F. Vande Woude Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
D.K. Watson Department of Pathology & Laboratory Medicine, The James E. Clyburn Research Center, Medical University of South Carolina, Charleston, SC, USA
A.T. Yeung Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press. Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index; Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:

International Institute of Anticancer Research
 1st km Kapandritiou-Kalamou Road,
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
 Tel: +30 22950 52945, Fax: +30 22950 53389
 e-mail: journals@iiar-anticancer.org. Web: www.iiar-anticancer.org; www.iiarjournals.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 9, 2012.

- A Race Against Breast Cancer, Frederiksberg, Denmark
 Albert Hung Foundation, U.K.
 Alfried Krupp von Bohlen und Halbach, Essen, Germany
 American Cancer Society, Atlanta, GA, U.S.A.
 American Heart Association, Dallas, TX, U.S.A.
 Antagoras AG, LLC., St Louis, MO, U.S.A.
- Breast Cancer Hope Foundation, London, U.K.
- California Breast Cancer Research Program (CBCRP),
 Oakland, CA, U.S.A.
 Canadian Institutes of Health Research, Ottawa, ON,
 Canada
 Cancer Research Wales, Cardiff, Wales, U.K.
 Cardiff University, Cardiff, Wales, U.K.
 Carolina's HealthCare System, Charlotte, NC, U.S.A.
 College of Science, George Mason University, Fairfax,
 VA, U.S.A.
 Compagnia di San Paolo, Turin, Italy
 Core Facility Microscopy, German Cancer Research Center
 (DKFZ), Heidelberg, Germany
- Danish Cancer Society, Copenhagen, Denmark
 Danish Center for Translational Breast Cancer Research
 (DCTB), Copenhagen, Denmark
 Danish Council for Independent Research, Copenhagen,
 Denmark
 Department of Genitourinary Medical Oncology, M.D.
 Anderson Cancer Center, Houston, TX, U.S.A.
 Department of Surgery, University of Michigan, Ann Arbor,
 MI, U.S.A.
 Department of Veterans Affairs, Washington, DC,
 U.S.A.
 Deutsche Krebshilfe, Bonn, Germany
- Fraternal Order of Eagles, Grove City, OH, U.S.A.
- GEM Tox Consultants & Labs, Inc., Greenville, NC, U.S.A.
 Genomics Research Centre, Griffith University, Southport,
 Australia
- Hector Foundation, Weinheim, Germany
 Hella-Bühler- Foundation, Heidelberg, Germany
- Institute of Molecular Systems Biology, ETH Zurich,
 Switzerland
- Johnson and Johnson, New Brunswick, NJ, U.S.A.
 Ministry of Education, Culture, Sports, Science, and
 Technology of Japan, Tokyo, Japan
- National Basic Research Program (973 Program), China
 National Cancer Institute (NCI), Bethesda, MD, U.S.A.
 National Institute of Health, Bethesda, MD, U.S.A.
 National Natural Science Foundation of China, China
 Novartis, Basel, Switzerland
- Odense University Hospital, Odense, Denmark
- Proteomics Laboratory, Carolina's HealthCare System, U.S.A.
- Sanford-Burnham Medical Research Institute, La Jolla,
 CA, U.S.A.
 Sino-Danish Breast Cancer Research Centre, University of
 Copenhagen, Copenhagen, Denmark
 Solms Foundation, Frankfurt/Main, Germany
 Susan G. Komen for the Cure, Dallas, TX, U.S.A.
- University of Heidelberg, Heidelberg, Germany
 University of Southern Denmark, Denmark
- Walter Schulz Foundation, Munich, Germany
 Wisconsin Breast Cancer Showhouse, Milwaukee, WI, U.S.A.

Contents, Volume 9, 2012

Number 1

Comparative Proteomic Analysis of a Cytosolic Fraction from $\beta 3$ Integrin-deficient Cells. J.A. BUSH, H. KITAURA, Y. MA, S.L. TEITELBAUM, F.P. ROSS, J.W. SMITH (<i>La Jolla, CA; St. Louis, MO, USA</i>).....	1
Look Who's Talking: Deregulated Signaling in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (<i>Heidelberg, Germany</i>).....	15
Plasma Biomarkers Distinguish Non-small Cell Lung Cancer from Asthma and Differ in Men and Women. E. IZBICKA, R.T. STREEPER, J.E. MICHALEK, C.L. LOUDEN, A. DIAZ III, D.R. CAMPOS (<i>San Antonio, TX, USA</i>)	27
* Review: Dissection of Aberrant GPCR Signaling in Tumorigenesis – A Systems Biology Approach. J. WU, N. XIE, X. ZHAO, E.C. NICE, C. HUANG (<i>Chengdu, PR China; Clayton, VIC, Australia</i>)	37
<i>KRAS</i> Mutation Is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAML, A. SOLTERMANN, H. MOCH, W. WEDER (<i>Zurich, Switzerland; Cambridge, MA, USA</i>)	51

Number 2

Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth. J. PAL, M. FULCINITI, P. NANJAPPA, L. BUON, Y.-T. TAI, P. TASSONE, N.C. MUNSHI, M.A. SHAMMAS (<i>Boston, MA, USA Catanzaro, Italy</i>)	55
Screening for Epigenetically Masked Genes in Colorectal Cancer Using 5-Aza-2'-deoxycytidine, Microarray and Gene Expression Profile. A. KHAMAS, T. ISHIKAWA, K. SHIMOKAWA, K. MOGUSHI, S. IIDA, M. ISHIGURO, H. MIZUSHIMA, H. TANAKA, H. UETAKE, K. SUGIHARA (<i>Tokyo, Japan</i>)	67
Preclinical Rationale for Combining an EGFR Antibody with Cisplatin/Gemcitabine for the Treatment of NSCLC. S. SAMAKOGLU, D.S. DEEVI, H. LI, S. WANG, M. MURPHY, C. BAO, R. BASSI, M. PREWETT, J.R. TONRA (<i>New York, NY, USA</i>)	77
Proteomic Analysis of Differently Archived Breast Cancer Tissues. A.-C. BOUGNOUX, A. MANGE, J. SOLASSOL (<i>Montpellier, France</i>).....	93
Proteomic Identification of Chaperonin-containing Tail-less Complex Polypeptide-1 Gamma Subunit as a p53-responsive Protein in Colon Cancer Cells. S.C. LEE, J. CHAN (<i>Singapore, Singapore</i>)	101

Number 3

<i>In Silico</i> Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (<i>Houston, TX, USA</i>)	109
A Genetic Variant Located in miR-423 is Associated with Reduced Breast Cancer Risk. R.A. SMITH, D.J. JEDLINSKI, P.N. GABROVSKA, S.R. WEINSTEIN, L. HAUPT, L.R. GRIFFITHS (<i>Gold Coast; Southport, QLD, Australia; Basel, Switzerland</i>)	115

* Review: Fully Human Targeted Cytotoxic Fusion Proteins: New Anticancer Agents on the Horizon. U.H. WEIDLE, G. GEORGES, U. BRINKMANN (<i>Penzberg, Germany</i>)	119
* Review: The Spectra Count Label-free Quantitation in Cancer Proteomics. W. ZHOU, L.A. LIOTTA, E.F. PETRICOIN (<i>Manassas, VA, USA</i>)	135
Microarray-based mRNA Expression Profiling of Leukemia Cells Treated with the Flavonoid, Casticin. C. RIGHESCHI, T. EICHHORN, A. KARIOTI, A.R. BILIA, T. EFFERTH (<i>Florence, Italy; Mainz, Germany</i>)	143
Modulation of Apoptosis Protein Profiles – Role of P-gp in HeLa Cells Exposed to Doxorubicin. B.M. GRUBER, J. KRZYSZTOŃ-RUSSJAN, I. BUBKO, M. KORONKIEWICZ, E.L. ANUSZEWSKA (<i>Warsaw, Poland</i>)....	153

Number 4

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (<i>Milwaukee, WI; Jackson, MS, USA</i>)	163
<i>MGMT</i> Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (<i>Pavia; Novara, Italy</i>).....	171
Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (<i>Greenville, Goldsboro, NC; Columbus, OH, USA</i>)	179
Influence of Plasminogen Activator Inhibitor-1 (<i>SERPINE1</i>) 4G/5G Polymorphism on Circulating SERPINE1 Antigen Expression in HCC Associated with Viral Infection. R. DIVELLA, A. MAZZOCCA, C. GADALETA, G. SIMONE, A. PARADISO, M. QUARANTA, A. DANIELE (<i>Bari, Italy</i>).....	193
The mRNA Expression of <i>DAPI</i> in Human Breast Cancer: Correlation with Clinicopathological Parameters. U. WAZIR, W.G. JIANG, A.K. SHARMA, K. MOKBEL (<i>London; Cardiff, Wales, UK</i>)	199
Increased Serum Level of RPMPS-1/S27 Protein in Patients with Various Types of Cancer Is Useful for the Early Detection, Prevention and Therapy. J.A. FERNANDEZ-POL (<i>Chesterfield, MO, USA</i>)	203

Number 5

Special Issue on Genomics and Proteomics of Metastasis

Identification of Differentially Expressed Proteins from Primary <i>versus</i> Metastatic Pancreatic Cancer Cells Using Subcellular Proteomics. K.Q. MCKINNEY, J.-G. LEE, D. SINDRAM, M.W. RUSSO, D.K. HAN, H.L. BONKOVSKY, S.-I. HWANG (<i>Charlotte, NC; Farmington, CT, USA</i>)	257
Identification of Markers Associated with Highly Aggressive Metastatic Phenotypes Using Quantitative Comparative Proteomics. M.G. TERP, R.R. LUND, O.N. JENSEN, R. LETH-LARSEN, H.J. DITZEL (<i>Odense, Denmark</i>)	265
* Review: Are we Missing the Target? – Cancer Stem Cells and Drug Resistance in Non-small Cell Lung Cancer. S. GOTTSCHLING, P.A. SCHNABEL, F.J.F. HERTH, E. HERPEL (<i>Heidelberg, Germany</i>)	275
Single Nucleotide Polymorphisms of Genes for EGF, TGF- β and TNF- α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEESE (<i>Frankfurt; Heidelberg, Germany; Xiamen, P.R. China</i>)	287

* Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÉ, A.M. GONZALEZ-ANGULO (<i>Houston, TX, USA</i>)	297
* Review: Breast Cancer Metastasis. O.J. SCULLY, B.-H. BAY, G. YIP, Y. YU (<i>Singapore, Singapore</i>)	311
Expression of Signal-induced Proliferation-associated Gene 1 (<i>SIPAI</i>), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (<i>Cardiff, UK; Beijing, PR China</i>)	321
* Review: Metastasis from Oral Cancer: An Overview. J. NOGUTI, C.F. DE MOURA, G.P. DE JESUS, V.H. DA SILVA, T.A. HOSSAKA, C.T. OSHIMA, D.A. RIBEIRO (<i>Sao Paulo, Brazil</i>)	329
KRAS Testing in Clinical Laboratory: Optimizing Targeted Therapy. L. MIRAVALLE, J.A. LEFFERTS, M. AL-HADDAD, G.J. TSONGALIS, L. CHENG (<i>Indianapolis, IN; Lebanon, NH, USA</i>)	337
Errata	343

Number 6

* Review: Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRETNALL, J.A. SMITH, K.A. KELLY (<i>Charlottesville, VA; Seattle, WA, USA</i>)	345
* Review: Genetically Engineered Fusion Proteins for Treatment of Cancer. U.H. WEIDLE, B. SCHNEIDER, G. GEORGES, U. BRINKMANN (<i>Penzberg, Germany</i>)	357
* Review: Cancer Metabolism: What we Can Learn from Proteomic Analysis by Mass Spectrometry. W. ZHOU, L.A. LIOTTA, E.F. PETRICOIN (<i>Manassas, VA, USA</i>)	373
Evidence of an Autocrine Role for Leptin and Leptin Receptor in Human Breast Cancer. U. WAZIR, W. AL SARAQBI, W.G. JIANG, K. MOKBEL (<i>London; Cardiff, Wales, UK</i>)	383
Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes Are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (<i>Tampa, FL, USA</i>)	389
Index 2012	397
* Reviews in Volume 9, pages: 37, 119, 135, 275, 297, 311, 329, 345, 357, 373.	

Subject Index

(Figures refer to page numbers)

- 20-HETE, 20-hydroxyeicosatetraenoic acid, eicosanoids, ovarian cancer, Ras, CYP4A/F, HRPTEC cells, 163
- 20-Hydroxyeicosatetraenoic acid, eicosanoids, ovarian cancer, Ras, CYP4A/F, 20-HETE, HRPTEC cells, 163
- 2D-E, p53, TCP-1 γ , tyrosine phosphorylation, centrosome, signal transduction, proteomics, cancer cells, MALDI-TOF-MS, HCT116 cells, 101
- 5-aza-2'-deoxycytidine, colorectal cancer, gene expression profiling, DNA methylation, microarray, 67
- Activity-based proteomics, lung adenocarcinoma, KRAS, myeloblastin, 51
- Adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Angiogenesis, antibody cytokine fusion proteins, chimeric extracellular receptor domains, decoy receptor, HER signaling; Fc-based fusion proteins, immune effector cell recruitment, treatment resistance, review, 357
- Antibody cytokine fusion proteins, angiogenesis, chimeric extracellular receptor domains, decoy receptor, HER signaling; Fc-based fusion proteins, immune effector cell recruitment, treatment resistance, review, 357
- Apoptosis inducing factor, cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, immuno-RNAses, granzymes, cellular trafficking, tumor targeting, review, 119
- Apoptosis, breast cancer, DAPI, tumour suppressor gene, PCR, autophagy, 199
- Apoptosis, sulindac, doxorubicin, gene expression profile, P-glycoprotein, 153
- Asthma, biomarker, non-small cell lung cancer, plasma, multiplex assay, autoantibodies, 27
- Autoantibodies, biomarker, non-small cell lung cancer, asthma, plasma, multiplex assay, 27
- Autocrine, leptin, autophagy, qPCR, breast cancer, COX2, hTERT, MCF7, MDA436, breast cell lines, 383
- Autophagy, breast cancer, apoptosis, DAPI, tumour suppressor gene, PCR, 199
- Autophagy, leptin, qPCR, breast cancer, COX2, hTERT, autocrine, MCF7, MDA436, breast cell lines, 383
- BAC cell line, barrett's adenocarcinoma, RAD51, DNA damage, phosphoinositide 3-kinase, wortmannin, FLO-1 cells, OE33 cells, 55
- Barrett's adenocarcinoma, RAD51, DNA damage, phosphoinositide 3-kinase, wortmannin, BAC cell line, FLO-1 cells, OE33 cells, 55
- Bioinformatics, adenocarcinoma, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Bioinformatics, cancer fusion genes, chromosomal translocations, transcriptome, genomics, cancer, evolutionary conservation of genes, UCSC genome browser assembly, 389
- Biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, prognosis, proteomics, recurrence, review, 345
- Biomarker, non-small cell lung cancer, asthma, plasma, multiplex assay, autoantibodies, 27
- Biomarkers, proteomics, metastasis, LRRRC59, NM2C5, LM3, CL16 cells, 265
- Breast cancer detection, metallopanstimulin-1, RPMPS-1/RPS27, p53, DNA repair protein, RP, ribosomal protein, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- Breast cancer, apoptosis, DAPI, tumour suppressor gene, PCR, autophagy, 199
- Breast cancer, leptin, autophagy, qPCR, COX2, hTERT, autocrine, MCF7, MDA436, breast cell lines, 383
- Breast cancer, metastasis, detection, invasion, migration, treatment, review, 311
- Breast cancer, metastasis, individualized therapy, review, 297
- Breast cancer, microRNA, miR-423, cancer risk, SNP, 115
- Breast cancer, proteomics, non-formalin-fixed, paraffin-embedded tissues, 93
- Breast cell lines, leptin, autophagy, qPCR, breast cancer, COX2, hTERT, autocrine, MCF7, MDA436, 383
- BXPC-3, pancreatic cancer, metastasis, subcellular proteomics, molecular signature, Capan-2, SU.86.86, Capan-1 cells, 257
- Cancer cells, p53, TCP-1 γ , tyrosine phosphorylation, centrosome, signal transduction, proteomics, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- Cancer fusion genes, chromosomal translocations, transcriptome, genomics, cancer, evolutionary conservation of genes, bioinformatics, UCSC genome browser assembly, 389
- Cancer metabolism, Warburg effect, oxidative stress, mass spectrometry, review, 373
- Cancer risk, microRNA, breast cancer, miR-423, SNP, 115
- Cancer stem cells, non-small cell lung cancer, drug resistance, targeted therapy, review, 275
- Cancer, biomarker, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, prognosis, proteomics, recurrence, review, 345
- Cancer, cancer fusion genes, chromosomal translocations, transcriptome, genomics, evolutionary conservation of genes, bioinformatics, UCSC genome browser assembly, 389
- Cancer, flavonoids, microarrays, multidrug resistance, natural products, pharmacogenomics, CCRF-CEM, CEM/ADR5000 cell lines, casticin, 143
- Cancer-proteomics, cathepsin B, integrin, isotope-coded affinity tags, protease, fractionation, GeLC-MS, HEK293 cells, 1
- Capan-1 cells, pancreatic cancer, metastasis, subcellular proteomics, molecular signature, BXPC-3, Capan-2, SU.86.86, 257
- Capan-2, pancreatic cancer, metastasis, subcellular proteomics, molecular signature, BXPC-3, SU.86.86, Capan-1 cells, 257

- Casticin, cancer, flavonoids, microarrays, multidrug resistance, natural products, pharmacogenomics, CCRF-CEM, CEM/ADR5000 cell lines, 143
- Cathepsin B, integrin, isotope-coded affinity tags, protease, cancer-proteomics, fractionation, GeLC-MS, HEK293 cells, 1
- CCRF-CEM, cancer, flavonoids, microarrays, multidrug resistance, natural products, pharmacogenomics, CEM/ADR5000 cell lines, casticin, 143
- Cell signaling, GPCR, systems biology, tumorigenesis, drug discovery, review, 37
- Cellular trafficking, cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, immuno-RNAses, granzymes, apoptosis inducing factor, tumor targeting, review, 119
- CEM/ADR5000 cell lines, cancer, flavonoids, microarrays, multidrug resistance, natural products, pharmacogenomics, CCRF-CEM, casticin, 143
- Centrosome, p53, TCP-1 γ , tyrosine phosphorylation, signal transduction, proteomics, cancer cells, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- Chimeric extracellular receptor domains, angiogenesis, antibody cytokine fusion proteins, decoy receptor, HER signaling; Fc-based fusion proteins, immune effector cell recruitment, treatment resistance, review, 357
- Chromosomal translocations, cancer fusion genes, transcriptome, genomics, cancer, evolutionary conservation of genes, bioinformatics, UCSC genome browser assembly, 389
- CL16 cells, proteomics, metastasis, biomarkers, LRRC59, NM2C5, LM3, 265
- Colorectal cancer, gene expression profiling, DNA methylation, microarray, 5-aza-2'-deoxycytidine, 67
- Colorectal cancer, KRAS mutation, molecular diagnostics, personalized medicine, targeted therapy, fine needle aspirate, FNA, shift termination assay, 337
- Colorectal carcinoma, signal-induced proliferation-associated gene 1, SIPA1, growth, migration and invasion, 321
- Complications, pancreatic cancer, polymorphism, growth factor, survival, 287
- COX2, leptin, autophagy, qPCR, breast cancer, hTERT, autocrine, MCF7, MDA436, breast cell lines, 383
- CYP4A/F, 20-hydroxyeicosatetraenoic acid, eicosanoids, ovarian cancer, Ras, 20-HETE, HRPTEC cells, 163
- Cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, immuno-RNAses, granzymes, apoptosis inducing factor, cellular trafficking, tumor targeting, review, 119
- DAPI, breast cancer, apoptosis, tumour suppressor gene, PCR, autophagy, 199
- Death receptors and corresponding ligands, cytotoxic enzyme effectors, endosome escape, immuno-RNAses, granzymes, apoptosis inducing factor, cellular trafficking, tumor targeting, review, 119
- Decoy receptor, angiogenesis, antibody cytokine fusion proteins, chimeric extracellular receptor domains, HER signaling; Fc-based fusion proteins, immune effector cell recruitment, treatment resistance, review, 357
- Detection, breast cancer, metastasis, invasion, migration, treatment, review, 311
- Differential gene expression, laser-capture microdissection, epithelium, stroma, pathway analysis, 15
- DNA damage, barrett's adenocarcinoma, RAD51, phosphoinositide 3-kinase, wortmannin, BAC cell line, FLO-1 cells, OE33 cells, 55
- DNA methylation, colorectal cancer, gene expression profiling, microarray, 5-aza-2'-deoxycytidine, 67
- DNA repair protein, metalloproteinase-1, RMPMS-1/RPS27, p53, RP, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- Doxorubicin, sulindac, gene expression profile, apoptosis, P-glycoprotein, 153
- Drug discovery, GPCR, systems biology, tumorigenesis, cell signaling, review, 37
- Drug resistance, non-small cell lung cancer, cancer stem cells, targeted therapy, review, 275
- EGFR, NSCLC, gemcitabine, platinum, microRNA, methylation, 77
- Eicosanoids, 20-hydroxyeicosatetraenoic acid, ovarian cancer, Ras, CYP4A/F, 20-HETE, HRPTEC cells, 163
- Endosome escape, cytotoxic enzyme effectors, death receptors and corresponding ligands, immuno-RNAses, granzymes, apoptosis inducing factor, cellular trafficking, tumor targeting, review, 119
- Epithelium, laser-capture microdissection, differential gene expression, stroma, pathway analysis, 15
- Evolutionary conservation of genes, cancer fusion genes, chromosomal translocations, transcriptome, genomics, cancer, bioinformatics, UCSC genome browser assembly, 389
- Fine needle aspirate, colorectal cancer, KRAS mutation, molecular diagnostics, personalized medicine, targeted therapy, FNA, shift termination assay, 337
- Flavonoids, cancer, microarrays, multidrug resistance, natural products, pharmacogenomics, CCRF-CEM, CEM/ADR5000 cell lines, casticin, 143
- FLO-1 cells, barrett's adenocarcinoma, RAD51, DNA damage, phosphoinositide 3-kinase, wortmannin, BAC cell line, OE33 cells, 55
- FNA, colorectal cancer, KRAS mutation, molecular diagnostics, personalized medicine, targeted therapy, fine needle aspirate, shift termination assay, 337
- Fractionation, cathepsin B, integrin, isotope-coded affinity tags, protease, cancer-proteomics, GeLC-MS, HEK293 cells, 1
- Functional profiling, gene expression, prostate cancer, in silico, functionality index, 109
- Functionality index, gene expression, prostate cancer, in silico, functional profiling, 109
- GeLC-MS, cathepsin B, integrin, isotope-coded affinity tags, protease, cancer-proteomics, fractionation, HEK293 cells, 1
- Gemcitabine, NSCLC, EGFR, platinum, microRNA, methylation, 77
- Gene expression profile, sulindac, doxorubicin, apoptosis, P-glycoprotein, 153
- Gene expression profiling, colorectal cancer, DNA methylation, microarray, 5-aza-2'-deoxycytidine, 67

- Gene expression, adenocarcinoma, bioinformatics, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Gene expression, prostate cancer, in silico, functional profiling, functionality index, 109
- Genomics, cancer fusion genes, chromosomal translocations, transcriptome, cancer, evolutionary conservation of genes, bioinformatics, UCSC genome browser assembly, 389
- Glioblastoma stem cells, MGMT, MDR, 171
- GPCR, systems biology, tumorigenesis, cell signaling, drug discovery, review, 37
- Granzymes, cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, immuno-RNases, apoptosis inducing factor, cellular trafficking, tumor targeting, review, 119
- Growth factor, pancreatic cancer, polymorphism, survival, complications, 287
- Growth factors, metalloproteinase-1, RMPMS-1/RPS27, p53, DNA repair protein, RP, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, 203
- HBV/HCV viral infection, hepatocellular carcinogenesis, SERPINE1 4G/5G polymorphism, 193
- HCT116 cells, p53, TCP-1 γ , tyrosine phosphorylation, centrosome, signal transduction, proteomics, cancer cells, 2D-E, MALDI-TOF-MS, 101
- HEK293 cells, cathepsin B, integrin, isotope-coded affinity tags, protease, cancer-proteomics, fractionation, GeLC-MS, 1
- Hepatocellular carcinogenesis, SERPINE1 4G/5G polymorphism, HBV/HCV viral infection, 193
- HER signaling; Fc-based fusion proteins, angiogenesis, antibody cytokine fusion proteins, chimeric extracellular receptor domains, decoy receptor, immune effector cell recruitment, treatment resistance, review, 357
- HRPTEC cells, 20-hydroxyeicosatetraenoic acid, eicosanoids, ovarian cancer, Ras, CYP4A/F, 20-HETE, 163
- hTERT, leptin, autophagy, qPCR, breast cancer, COX2, autocrine, MCF7, MDA436, breast cell lines, 383
- Imaging agent, biomarker, cancer, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, prognosis, proteomics, recurrence, review, 345
- Immune effector cell recruitment, angiogenesis, antibody cytokine fusion proteins, chimeric extracellular receptor domains, decoy receptor, HER signaling; Fc-based fusion proteins, treatment resistance, review, 357
- Immuno-RNases, cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, granzymes, apoptosis inducing factor, cellular trafficking, tumor targeting, review, 119
- In silico, gene expression, prostate cancer, functional profiling, functionality index, 109
- Individualized therapy, breast cancer, metastasis, review, 297
- Integrin, cathepsin B, isotope-coded affinity tags, protease, cancer-proteomics, fractionation, GeLC-MS, HEK293 cells, 1
- Invasion, breast cancer, metastasis, detection, migration, treatment, review, 311
- Isotope-coded affinity tags, cathepsin B, integrin, protease, cancer-proteomics, fractionation, GeLC-MS, HEK293 cells, 1
- KRAS mutation, colorectal cancer, molecular diagnostics, personalized medicine, targeted therapy, fine needle aspirate, FNA, shift termination assay, 337
- KRAS, lung adenocarcinoma, activity-based proteomics, myeloblastin, 51
- Label-free quantitation, mass spectrometry, spectra count, proteomics, review, 135
- Laser-capture microdissection, differential gene expression, epithelium, stroma, pathway analysis, 15
- LCM, adenocarcinoma, bioinformatics, gene expression, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Leptin, autophagy, qPCR, breast cancer, COX2, hTERT, autocrine, MCF7, MDA436, breast cell lines, 383
- LM3, proteomics, metastasis, biomarkers, LRRCS9, NM2C5, CL16 cells, 265
- LRRCS9, proteomics, metastasis, biomarkers, NM2C5, LM3, CL16 cells, 265
- Lung adenocarcinoma, activity-based proteomics, KRAS, myeloblastin, 51
- MALDI-TOF-MS, p53, TCP-1 γ , tyrosine phosphorylation, centrosome, signal transduction, proteomics, cancer cells, 2D-E, HCT116 cells, 101
- Mass spectrometry, cancer metabolism, Warburg effect, oxidative stress, review, 373
- Mass spectrometry, label-free quantitation, spectra count, proteomics, review, 135
- Mass spectroscopy (MS), biomarker, cancer, imaging agent, metastatic potential, metastasis, personalized medicine, prognosis, proteomics, recurrence, review, 345
- MCF7, leptin, autophagy, qPCR, breast cancer, COX2, hTERT, autocrine, MDA436, breast cell lines, 383
- MDA436, leptin, autophagy, qPCR, breast cancer, COX2, hTERT, autocrine, MCF7, breast cell lines, 383
- MDR, MGMT, glioblastoma stem cells, 171
- Metalloproteinase-1, RMPMS-1/RPS27, p53, DNA repair protein, RP, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- Metastasis, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, personalized medicine, prognosis, proteomics, recurrence, review, 345
- Metastasis, breast cancer, detection, invasion, migration, treatment, review, 311
- Metastasis, breast cancer, individualized therapy, review, 297
- Metastasis, oral cancer, review, 329
- Metastasis, pancreatic cancer, subcellular proteomics, molecular signature, BXP-3, Capan-2, SU.86.86, Capan-1 cells, 257
- Metastasis, proteomics, biomarkers, LRRCS9, NM2C5, LM3, CL16 cells, 265
- Metastatic potential, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastasis, personalized medicine, prognosis, proteomics, recurrence, review, 345
- Methylation, NSCLC, EGFR, gemcitabine, platinum, microRNA, 77

- MGB, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- MGMT, MDR, glioblastoma stem cells, 171
- Microarray, colorectal cancer, gene expression profiling, DNA methylation, 5-aza-2'-deoxycytidine, 67
- Microarrays, adenocarcinoma, bioinformatics, gene expression, LCM, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Microarrays, cancer, flavonoids, multidrug resistance, natural products, pharmacogenomics, CCRF-CEM, CEM/ADR5000 cell lines, casticin, 143
- MicroRNA, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, screening test, non-invasive diagnosis, 179
- MicroRNA, breast cancer, miR-423, cancer risk, SNP, 115
- MicroRNA, NSCLC, EGFR, gemcitabine, platinum, methylation, 77
- Migration and invasion, signal-induced proliferation-associated gene 1, SIPA1, colorectal carcinoma, growth, 321
- Migration, breast cancer, metastasis, detection, invasion, treatment, review, 311
- MiR-423, microRNA, breast cancer, cancer risk, SNP, 115
- MiRNAs, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, microRNA, screening test, non-invasive diagnosis, 179
- Molecular diagnostics, colorectal cancer, KRAS mutation, personalized medicine, targeted therapy, fine needle aspirate, FNA, shift termination assay, 337
- Molecular signature, pancreatic cancer, metastasis, subcellular proteomics, BXPC-3, Capan-2, SU.86.86, Capan-1 cells, 257
- Multidrug resistance, cancer, flavonoids, microarrays, natural products, pharmacogenomics, CCRF-CEM, CEM/ADR5000 cell lines, casticin, 143
- Multiplex assay, biomarker, non-small cell lung cancer, asthma, plasma, autoantibodies, 27
- Myeloblastin, lung adenocarcinoma, activity-based proteomics, KRAS, 51
- Natural products, cancer, flavonoids, microarrays, multidrug resistance, pharmacogenomics, CCRF-CEM, CEM/ADR5000 cell lines, casticin, 143
- NM2C5, proteomics, metastasis, biomarkers, LRRC59, LM3, CL16 cells, 265
- Non-formalin-fixed, proteomics, paraffin-embedded tissues, breast cancer, 93
- Non-invasive diagnosis, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, 179
- Non-small cell lung cancer, biomarker, asthma, plasma, multiplex assay, autoantibodies, 27
- Non-small cell lung cancer, cancer stem cells, drug resistance, targeted therapy, review, 275
- NSCLC, EGFR, gemcitabine, platinum, microRNA, methylation, 77
- OE33 cells, barrett's adenocarcinoma, RAD51, DNA damage, phosphoinositide 3-kinase, wortmannin, BAC cell line, FLO-1 cells, 55
- Oncogenesis, metalloproteinase-1, RPMS-1/RPS27, p53, DNA repair protein, RP, ribosomal protein, breast cancer detection, zinc finger proteins, tumor marker, growth factors, 203
- Oral cancer, metastasis, review, 329
- Ovarian cancer, 20-hydroxyeicosatetraenoic acid, eicosanoids, Ras, CYP4A/F, 20-HETE, HRPTEC cells, 163
- Oxidative stress, cancer metabolism, Warburg effect, mass spectrometry, review, 373
- P53, metalloproteinase-1, RPMS-1/RPS27, DNA repair protein, RP, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- P53, TCP-1 γ , tyrosine phosphorylation, centrosome, signal transduction, proteomics, cancer cells, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- Pancreatic cancer, metastasis, subcellular proteomics, molecular signature, BXPC-3, Capan-2, SU.86.86, Capan-1 cells, 257
- Pancreatic cancer, polymorphism, growth factor, survival, complications, 287
- Paraffin-embedded tissues, proteomics, non-formalin-fixed, breast cancer, 93
- Pathway analysis, laser-capture microdissection, differential gene expression, epithelium, stroma, 15
- PCR, breast cancer, apoptosis, DAP1, tumour suppressor gene, autophagy, 199
- Personalized medicine, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, prognosis, proteomics, recurrence, review, 345
- Personalized medicine, colorectal cancer, KRAS mutation, molecular diagnostics, targeted therapy, fine needle aspirate, FNA, shift termination assay, 337
- P-glycoprotein, sulindac, doxorubicin, gene expression profile, apoptosis, 153
- Pharmacogenomics, cancer, flavonoids, microarrays, multidrug resistance, natural products, CCRF-CEM, CEM/ADR5000 cell lines, casticin, 143
- Phosphoinositide 3-kinase, barrett's adenocarcinoma, RAD51, DNA damage, wortmannin, BAC cell line, FLO-1 cells, OE33 cells, 55
- Plasma, biomarker, non-small cell lung cancer, asthma, multiplex assay, autoantibodies, 27
- Platinum, NSCLC, EGFR, gemcitabine, microRNA, methylation, 77
- Polymorphism, pancreatic cancer, growth factor, survival, complications, 287
- Primers, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Probes, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, QC, RNA, RT-qPCR,

- staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Prognosis, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, proteomics, recurrence, review, 345
- Prostate cancer, gene expression, in silico, functional profiling, functionality index, 109
- Protease, cathepsin B, integrin, isotope-coded affinity tags, cancer-proteomics, fractionation, GeLC-MS, HEK293 cells, 1
- Proteomics, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, prognosis, recurrence, review, 345
- Proteomics, mass spectrometry, label-free quantitation, spectra count, review, 135
- Proteomics, metastasis, biomarkers, LRRC59, NM2C5, LM3, CL16 cells, 265
- Proteomics, non-formalin-fixed, paraffin-embedded tissues, breast cancer, 93
- Proteomics, p53, TCP-1 γ , tyrosine phosphorylation, centrosome, signal transduction, cancer cells, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- QC, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- QPCR, leptin, autophagy, breast cancer, COX2, hTERT, autocrine, MCF7, MDA436, breast cell lines, 383
- RAD51, barrett's adenocarcinoma, DNA damage, phosphoinositide 3-kinase, wortmannin, BAC cell line, FLO-1 cells, OE33 cells, 55
- Ras, 20-hydroxyeicosatetraenoic acid, eicosanoids, ovarian cancer, CYP4A/F, 20-HETE, HRPTEC cells, 163
- Recurrence, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, prognosis, proteomics, review, 345
- Review, angiogenesis, antibody cytokine fusion proteins, chimeric extracellular receptor domains, decoy receptor, HER signaling; Fc-based fusion proteins, immune effector cell recruitment, treatment resistance, 357
- Review, biomarker, cancer, imaging agent, mass spectroscopy (MS), metastatic potential, metastasis, personalized medicine, prognosis, proteomics, recurrence, 345
- Review, breast cancer, metastasis, detection, invasion, migration, treatment, 311
- Review, breast cancer, metastasis, individualized therapy, 297
- Review, cancer metabolism, Warburg effect, oxidative stress, mass spectrometry, 373
- Review, cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, immuno-RNases, granzymes, apoptosis inducing factor, cellular trafficking, tumor targeting, 119
- Review, GPCR, systems biology, tumorigenesis, cell signaling, drug discovery, 37
- Review, mass spectrometry, label-free quantitation, spectra count, proteomics, 135
- Review, non-small cell lung cancer, cancer stem cells, drug resistance, targeted therapy, 275
- Review, oral cancer, metastasis, 329
- Ribosomal protein, metallopanstimulin-1, RPMPS-1/RPS27, p53, DNA repair protein, RP, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- RNA, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RT-qPCR, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- RP, metallopanstimulin-1, RPMPS-1/RPS27, p53, DNA repair protein, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- RPMPS-1/RPS27, metallopanstimulin-1, p53, DNA repair protein, RP, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, tumor marker, growth factors, 203
- RT-qPCR, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, staging, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Screening test, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, statistics, miRNAs, microRNA, non-invasive diagnosis, 179
- SERPINE1 4G/5G polymorphism, hepatocellular carcinogenesis, HBV/HCV viral infection, 193
- Shift termination assay, colorectal cancer, KRAS mutation, molecular diagnostics, personalized medicine, targeted therapy, fine needle aspirate, FNA, 337
- Signal transduction, p53, TCP-1 γ , tyrosine phosphorylation, centrosome, proteomics, cancer cells, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- Signal-induced proliferation-associated gene 1, SIPA1, colorectal carcinoma, growth, migration and invasion, 321
- SIPA1, signal-induced proliferation-associated gene 1, colorectal carcinoma, growth, migration and invasion, 321
- SNP, microRNA, breast cancer, miR-423, cancer risk, 115
- Spectra count, mass spectrometry, label-free quantitation, proteomics, review, 135
- Staging, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, statistics, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Statistics, adenocarcinoma, bioinformatics, gene expression, LCM, microarrays, MGB, primers, probes, QC, RNA, RT-qPCR, staging, miRNAs, microRNA, screening test, non-invasive diagnosis, 179
- Stroma, laser-capture microdissection, differential gene expression, epithelium, pathway analysis, 15
- SU.86.86, pancreatic cancer, metastasis, subcellular proteomics, molecular signature, BXPC-3, Capan-2, Capan-1 cells, 257
- Subcellular proteomics, pancreatic cancer, metastasis, molecular signature, BXPC-3, Capan-2, SU.86.86, Capan-1 cells, 257
- Sulindac, doxorubicin, gene expression profile, apoptosis, P-glycoprotein, 153
- Survival, pancreatic cancer, polymorphism, growth factor, complications, 287

- Systems biology, GPCR, tumorigenesis, cell signaling, drug discovery, review, 37
- Targeted therapy, colorectal cancer, KRAS mutation, molecular diagnostics, personalized medicine, fine needle aspirate, FNA, shift termination assay, 337
- Targeted therapy, non-small cell lung cancer, cancer stem cells, drug resistance, review, 275
- TCP-1 γ , p53, tyrosine phosphorylation, centrosome, signal transduction, proteomics, cancer cells, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- Transcriptome, cancer fusion genes, chromosomal translocations, genomics, cancer, evolutionary conservation of genes, bioinformatics, UCSC genome browser assembly, 389
- Treatment resistance, angiogenesis, antibody cytokine fusion proteins, chimeric extracellular receptor domains, decoy receptor, HER signaling; Fc-based fusion proteins, immune effector cell recruitment, review, 357
- Treatment, breast cancer, metastasis, detection, invasion, migration, review, 311
- Tumor marker, metalloproteinase-1, RMPMS-1/RPS27, p53, DNA repair protein, RP, ribosomal protein, breast cancer detection, zinc finger proteins, oncogenesis, growth factors, 203
- Tumor targeting, cytotoxic enzyme effectors, death receptors and corresponding ligands, endosome escape, immunorNases, granzymes, apoptosis inducing factor, cellular trafficking, review, 119
- Tumorigenesis, GPCR, systems biology, cell signaling, drug discovery, review, 37
- Tumour suppressor gene, breast cancer, apoptosis, DAPI, PCR, autophagy, 199
- Tyrosine phosphorylation, p53, TCP-1 γ , centrosome, signal transduction, proteomics, cancer cells, 2D-E, MALDI-TOF-MS, HCT116 cells, 101
- UCSC genome browser assembly, cancer fusion genes, chromosomal translocations, transcriptome, genomics, cancer, evolutionary conservation of genes, bioinformatics, 389
- Warburg effect, cancer metabolism, oxidative stress, mass spectrometry, review, 373
- Wortmannin, barrett's adenocarcinoma, RAD51, DNA damage, phosphoinositide 3-kinase, BAC cell line, FLO-1 cells, OE33 cells, 55
- Zinc finger proteins, metalloproteinase-1, RMPMS-1/RPS27, p53, DNA repair protein, RP, ribosomal protein, breast cancer detection, oncogenesis, tumor marker, growth factors, 203

Authors Index

(Figures refer to page numbers)

- Abba M, 15
 Aghajany M, 15
 Ahmed FE, 179
 Al Sarakbi W, 383
 Alexanian A, 163
 Al-Haddad M, 337
 Allgayer H, 15
 Allison RR, 179
 Amed NC, 179
 Annovazzi L, 171
 Anuszcwaska EL, 153
 Arni S, 51
 Atkins JN, 179
 Bao C, 77
 Bassi R, 77
 Bay B-H, 311
 Benner A, 15
 Bilia AR, 143
 Blanck G, 389
 Bonkovsky HL, 257
 Bonnerup C, 179
 Bougnoux A-C, 93
 Brentnall TA, 345
 Brinkmann U, 119, 357
 Brinton LT, 345
 Bubko I, 153
 Buon L, 55
 Burgess C, 51
 Bush JA, 1
 Byun J, 109
 Caldera V, 171
 Campos DR, 27
 Casey M, 179
 Chan J, 101
 Chen R, 389
 Cheng L, 337
 Collaud S, 51
 Da Silva VH, 329
 Daniele A, 193
 De Jesus GP, 329
 De Moura CF, 329
 Deevi DS, 77
 Diaz III A, 27
 Ditzel HJ, 265
 Divella R, 193
 Efferth T, 143
 Eichhorn T, 143
 Fernandez-Pol JA, 203
 Fulciniti M, 55
 Gabrovská PN, 115
 Gadaleta C, 193
 Georges G, 119, 357
 Gonzalez-Angulo AM, 297
 Gorlov IP, 109
 Gottschling S, 275
 Griffiths LR, 115
 Gruber BM, 153
 Han DK, 257
 Hargest R, 321
 Haupt L, 115
 Herpel E, 275
 Herrle F, 287
 Herth FJF, 275
 Hillinger S, 51
 Hossaka TA, 329
 Huang C, 37
 Hwang S-I, 257
 Iida S, 67
 Ishiguro M, 67
 Ishikawa T, 67
 Izbicka E, 27
 Jedlinski DJ, 115
 Jensen ON, 265
 Ji J, 321
 Ji K, 321
 Jiang WG, 199, 321, 383
 Karioti A, 143
 Keese M, 287
 Kelly KA, 345
 Khamas A, 67
 Kitaura H, 1
 Korn B, 15
 Koronkiewicz M, 153
 Kroll W, 51
 Krzysztoń-Russjan J, 153
 Laufs S, 15
 Lee J-G, 257
 Lee SC, 101
 Lefferts JA, 337
 Leth-Larsen R, 265
 Li H, 77
 Liotta LA, 135, 373
 Logothetis CJ, 109
 Loudon CL, 27
 Lund RR, 265
 Ma Y, 1
 Mange A, 93
 Martin TA, 321
 Mazzocca A, 193
 McKinney KQ, 257
 Mellai M, 171
 Michalek JE, 27
 Miller B, 163
 Miravalle L, 337
 Mizushima H, 67
 Moch H, 51
 Mogushi K, 67
 Mokbel K, 199, 383
 Monzeglio O, 171
 Morton DT, 389
 Munshi NC, 55
 Murphy M, 77
 Nanjappa P, 55
 Naziri W, 179
 Nice EC, 37
 Niedergethmann M, 287
 Noguti J, 329
 Nuovo GJ, 179
 Oshima CT, 329
 Pal J, 55
 Paradiso A, 193
 Pava LM, 389
 Petricoin EF, 135, 373
 Piazzi A, 171
 Prewett M, 77
 Quaranta M, 193
 Ribeiro DA, 329
 Righeschi C, 143
 Roman RJ, 163
 Ross FP, 1
 Ruge F, 321
 Russo MW, 257
 Samakoglu S, 77
 Schiffer D, 171
 Schnabel PA, 275
 Schneider B, 357
 Schraml P, 51
 Scully OJ, 311
 Shamma MA, 55
 Sharma AK, 199
 Shimokawa K, 67
 Simone G, 193
 Sindram D, 257
 Smith JA, 345
 Smith JW, 1
 Smith RA, 115
 Solassol J, 93
 Soltermann A, 51
 Sorokin A, 163
 Streeper RT, 27
 Sugihara K, 67
 Tai Y-T, 55
 Tanaka H, 67
 Tassone P, 55
 Teitelbaum SL, 1
 Terp MG, 265
 Toms A-M, 321
 Tonra J,R, 77
 Trapé AP, 297
 Tsongalis GJ, 337
 Uetake H, 67
 Vos PW, 179
 Wang S, 77
 Wazir U, 199, 383
 Weder W, 51
 Weidle UH, 119, 357
 Weinstein SR, 115
 Wiedl T, 51
 Wiley JE, 179
 Wu G, 287
 Wu J, 37
 Xie N, 37
 Ye L, 321
 Yip G, 311
 Yu Y, 311
 Zhang L, 287
 Zhao X, 37
 Zhou W, 135, 373

Erratum

Volume 8 (2011), No. 3, page 105:

The e-mail of the corresponding author should read:

fernandezpol@att.net

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: www.iiar-anticancer.org, www.cgp.iiarjournals.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: journals@iiar-anticancer.org (Editorial Office), editor@iiar-anticancer.org (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Annual Subscription. CANCER GENOMICS & PROTEOMICS is converted to an online-only open access journal from January 2013 (Volume 10)

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.